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ABSTRACT
Objectives Develop recommendations for women’s
health issues and family planning in systemic lupus
erythematosus (SLE) and/or antiphospholipid syndrome
(APS).
Methods Systematic review of evidence followed by
modiﬁed Delphi method to compile questions, elicit expert
opinions and reach consensus.
Results Family planning should be discussed as early as
possible after diagnosis. Most women can have successful
pregnancies and measures can be taken to reduce the risks
of adverse maternal or fetal outcomes. Risk stratiﬁcation
includes disease activity, autoantibody proﬁle, previous
vascular and pregnancy morbidity, hypertension and
the use of drugs (emphasis on beneﬁts from
hydroxychloroquine and antiplatelets/anticoagulants).
Hormonal contraception and menopause replacement
therapy can be used in patients with stable/inactive disease
and low risk of thrombosis. Fertility preservation with
gonadotropin-releasing hormone analogues should be
considered prior to the use of alkylating agents. Assisted
reproduction techniques can be safely used in patients with
stable/inactive disease; patients with positive
antiphospholipid antibodies/APS should receive
anticoagulation and/or low-dose aspirin. Assessment of
disease activity, renal function and serological markers is
important for diagnosing disease ﬂares and monitoring
for obstetrical adverse outcomes. Fetal monitoring
includes Doppler ultrasonography and fetal biometry,
particularly in the third trimester, to screen for placental
insufﬁciency and small for gestational age fetuses.
Screening for gynaecological malignancies is similar to
the general population, with increased vigilance for
cervical premalignant lesions if exposed to
immunosuppressive drugs. Human papillomavirus
immunisation can be used in women with stable/inactive
disease.
Conclusions Recommendations for women’s health
issues in SLE and/or APS were developed using an
evidence-based approach followed by expert
consensus.
INTRODUCTION
Systemic lupus erythematosus (SLE) and the anti-
phospholipid syndrome (APS), SLE-associated or
primary APS, affect mostly women of childbearing
age. Several ‘unmet needs’ in the management of
reproductive and other women’s health issues may
impact on personal relationships and the decision
to have children.1 Because of earlier recognition
of disease and advances in medical treatment,
family planning has gained greater importance.2–4
Concerns include the effect of pregnancy on mater-
nal disease, the impact of disease activity on fetal
health and the safety of medications during preg-
nancy and breast feeding. Assessment of fertility
and feasibility of assisted reproduction techniques
(ARTs), use of contraception, management of
menopause and surveillance against malignancies
need to be addressed. We gathered a multidiscip-
linary panel of experts to develop evidence-
based recommendations on the management of
family planning and women’s health issues in
SLE and/or APS.
METHODS
We followed the European League Against
Rheumatism (EULAR) standardised operating pro-
cedures5 and the Appraisal of Guidelines Research
and Evaluation instrument. Through a Delphi-
based approach, the committee selected 12 research
questions further edited for systematic literature
review (see online supplementary table S1). We
searched PubMed using arrays of relevant terms; all
English-language publications up to December
2014 were considered. A hand search was also per-
formed in October 2015. Retrieved items were
reﬁned based on abstract, full-text content and
number of included patients. A detailed presenta-
tion of the literature review is given in the online
supplementary table S2. Evidence was categorised
based on the design and validity of available studies
and the strength of the statements was graded (see
online supplementary table S3). After rounds of
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Table 1 Recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in
patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)
LoA
Statement/recommendation Mean (SD) Median (IQR)
1. Preconception counselling and risk stratification
1.1 In women with SLE, major risk factors for adverse maternal and fetal outcomes include active/flaring SLE (1/A), especially active nephritis
(1/A), history of lupus nephritis (2/B) and presence of aPL/APS* (1/A).
1.1.1 Blood pressure monitoring (2/B), use of safe medications to control disease activity (emphasis on HCQ (2/B)) and limiting glucocorticoids
exposure (2/B) are essential measures.
1.2 In women with APS (primary or SLE-APS), risk factors include high-risk aPL profile (lupus anticoagulant, multiple aPL, moderate to high
titre aPL) (1/A), coexisting SLE (2/B), history of vascular/thrombotic APS (2/B) and of previous adverse pregnancy complications (2/B).
1.2.1 Blood pressure monitoring (3/C) and use of antiplatelet and/or anticoagulant therapy (rated at statement 9) are of fundamental
importance.
10 (0.2) 10 (0)
2. Contraceptive measures
2.1 Women with SLE should be counselled about the use of effective contraceptive measures (oral contraceptives, subcutaneous implants, IUD),
based on their disease activity and thrombotic risk (particularly aPL status). IUD can be offered to all the patients with SLE and/or APS free
of any gynaecological contraindication (1/A).
2.2 In patients with stable/inactive SLE and negative aPL, combined hormonal contraceptives can be considered (1/A). In women with positive
aPL with or without definite APS, hormonal contraception (with progesterone only) must be carefully weighed against the risk of thrombosis
(2/B).
9.9 (0.4) 10 (0)
3. Risk factors for reduced fertility
Women with SLE who wish to plan a pregnancy should be counselled about fertility issues, especially the adverse outcomes associated with
increasing age and the use of alkylating agents (1/A). Treatment with alkylating agents should be balanced against the risk of ovarian
dysfunction.
9.8 (0.4) 10 (0)
4. Preservation of fertility
Fertility preservation methods, especially GnRH analogues, should be considered for all menstruating women with SLE who are going to
receive alkylating agents (2/B).
9.5 (0.7) 10 (1)
5. Assisted reproduction techniques
5.1 Assisted reproduction techniques, such as ovulation induction treatments and in vitro fertilisation protocols, can be safely used in patients
with SLE with stable/inactive disease (3/C).
5.2 Patients with positive aPL/APS should receive anticoagulation (at the dosage as would be recommended during pregnancy) and/or low-dose
aspirin (3/D).
9.6 (0.6) 10 (1)
6. Predictive biomarkers for maternal disease activity in SLE pregnancy
In pregnant women with SLE, assessment of disease activity (1/A)—including renal function parameters (2/B) and serological markers
(serum C3/C4, anti-dsDNA titres) (2/B)—is recommended to monitor for obstetrical adverse outcomes and disease flares.
9.9 (0.3) 10 (0)
7. Pregnancy monitoring
7.1 Women with SLE and/or APS should undergo supplementary fetal surveillance with Doppler ultrasonography and biometric parameters,
particularly in the third trimester to screen for placental insufficiency and small for gestational age fetuses (3/D).
7.2 Fetal echocardiography is recommended in cases of suspected fetal dysrhythmia or myocarditis, especially in patients with positive anti-Ro/
SSA and/or anti-La/SSB antibodies (2/C)†.
9.7 (0.5) 10 (1)
8. Drugs for the prevention and management of SLE flares during pregnancy
8.1 HCQ (1/B), oral glucocorticoids, azathioprine, ciclosporin A and tacrolimus (all 3/C) can be used to prevent or manage SLE flares during
pregnancy.
8.2 Moderate-to-severe flares can be managed with additional strategies, including glucocorticoids intravenous pulse therapy, intravenous
immunoglobulin and plasmapheresis (all 3/C).
8.3 Mycophenolic acid, cyclophosphamide, leflunomide and methotrexate should be avoided.
9.7 (0.7) 10 (0)
9. Adjunct treatment during pregnancy
9.1 HCQ is recommended preconceptionally and throughout pregnancy for patients with SLE (2/B).
9.2 Women with SLE at risk of pre-eclampsia (especially those with lupus nephritis or positive aPL) should receive LDA (2/C). In women with
SLE-associated APS or primary APS, combination treatment with LDA and heparin is recommended to decrease the risk of adverse pregnancy
outcomes (1/A).
9.3 Supplementation with calcium, vitamin D and folic acid should be offered as in the general population (–/D). Measuring blood vitamin D
levels should be considered after pregnancy is confirmed (–/D).
9.8 (0.4) 10 (0)
10. Menopause and HRT
HRT can be used for the management of severe vasomotor menopausal manifestations in SLE women with stable/inactive disease and
negative aPL (1/A). The use of HRT in patients with positive aPL should be carefully weighed against the risk of thrombosis and
cardiovascular disease (–/D).
9.6 (0.6) 10 (1)
11. Screening for malignancies
Women with SLE and/or APS should undergo screening for malignancies similar to the general population (–/D). Women with SLE, especially
those exposed to immunosuppressive drugs, are at higher risk of cervical premalignant lesions and should be monitored with vigilance (2/B).
9.8 (0.4) 10 (0)
12. HPV vaccination
HPV immunisation can be considered in women with SLE and/or APS and stable/inactive disease (3/D).
9.2 (1.6) 10 (1)
For each statement or item, the LoE (range 1–3) and the GoR (range A–D) is given in parentheses (refer to online supplementary table S1). In the right-hand columns, the LoA among
experts is reported as mean (SD) and median (IQR) values. A score of 10 represents the highest level of agreement.
*aPL and APS are defined according to the updated international consensus criteria.6 For aPL assays, please see the footnotes of table 2.
†The substatement on fetal echo in women with SLE/APS and positive anti-Ro/La is rated with LoE=2 (ie, sufficient evidence for the association between anti-Ro/La and congenital heart
block) but GoR=C due to lack of strong evidence for the clinical implications of this association, namely for the efficacy of interventions.
anti-dsDNA, anti-double-stranded DNA antibodies; aPL, antiphospholipid antibodies; GnRH, gonadotropin-releasing hormone; GoR, grade of recommendation; HCQ, hydroxychloroquine;
HPV, human papillomavirus; HRT, hormone replacement therapy; IUD, intrauterine devices; LDA, low-dose aspirin; LoA, level of agreement; LoE, level of evidence.
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discussions, the committee arrived at 12 ﬁnal statements (table 1).
Each member rated her/his agreement with each statement.
RESULTS AND DISCUSSION
Scope and overarching principles
These recommendations have been devised with the intention
of helping physicians involved in the care of patients with SLE
and/or APS and facilitating physician–patient communication.
They recognise an implicit need for change in the mindset of
health professionals, shifting from caution against pregnancy
towards embracement of pregnancy. Accordingly, family plan-
ning should be discussed from the ﬁrst physician–patient
encounter and reinforced thereafter. Health professionals
should support the patient and her family in their decisions
regarding family planning by discussing individual pregnancy
risks. Reports on the long-term follow-up of SLE and/or APS
offspring are few,7–10 showing a reassuring picture on the health
conditions of the children, with the exception of some cases of
neurodevelopmental alterations11–13 that need further conﬁrm-
ation before they are linked to maternal disease.
Recommendations
Preconception counselling and risk stratiﬁcation
Assessment of risk factors for adverse maternal and fetal out-
comes in pregnant women with SLE and/or APS is crucial for
preconception counselling and implementing appropriate
preventive strategies and patient-tailored monitoring plan before
and during pregnancy (table 2).
In SLE women (with or without APS), prematurity, pre-
eclampsia and eclampsia/Hemolysis, Elevated Liver enzyme
levels, Low Platelet count (HELLP) rates approximate 25–35%,
10–15% and 1.0–1.5%, respectively.19 24 25 44 51 52 In APS
women (primary or SLE-related), the respective frequencies
approximate 25–35%, 10–20% and 3.0–5.0%.28 29 53 54
During pregnancy, risk factors associated with adverse out-
comes include active/ﬂaring SLE (OR 12.7 for pre-eclampsia/
eclampsia;55 19.0 for emergency caesarean section;56 3.0 for
early fetal loss;20 5.5 for preterm delivery),21 19 active nephritis
(OR 5.3 for any adverse maternal outcome),57 hypertension
(OR 4.8–7.3 for pre-eclampsia;52 relative risk (RR) 1.8 for
preterm birth)22 and use of glucocorticoids, especially at main-
tenance dose ≥10–20 mg/day of prednisone equivalent (OR 3.5
for preterm birth).58 59 Discontinuation of hydroxychloroquine
(HCQ) is related to an increased risk for SLE exacerbations
during pregnancy,24 33 56 and a single placebo-controlled study
has suggested a beneﬁcial effect of HCQ on maternal disease
activity during pregnancy.60
Contraceptive measures
Women with SLE and/or APS should be counselled about
contraception, especially for the prevention of unwanted preg-
nancies during high disease activity periods and intake of terato-
genic drugs. Effective contraceptive measures should be
Table 2 Checklist of parameters to be considered for preconception counselling and risk stratification in women with systemic lupus
erythematosus (SLE) and/or antiphospholipid syndrome (APS)
Disease-related risk factors Prognostic implications
SLE activity/flares* (in the last 6–12 months
or at conception)
Increased risk for (i) maternal disease activity (RR 2.1 for subsequent flare during pregnancy and puerperium);14
(ii) hypertensive complications (OR 1.8 for PE);15 (iii) fetal morbidity and mortality (OR 5.7 for pregnancy loss,16 3.5 for
IUGR17 6.5 for preterm delivery)14 15 17–22
Lupus nephritis (history or active at
conception†)
Strong predictor of poor maternal (RR 9.0 for renal flare during/after pregnancy)23 and fetal outcome(s) (OR 7.3 for fetal loss
and 18.9 for preterm delivery)24 25
Serological (serum C3/C4, anti-dsDNA titres)
activity
Increased risk for maternal SLE flares during pregnancy (OR 5.3)14 and pregnancy loss23 26 27
Previous adverse pregnancy outcome(s) APS: increased risk for pregnancy complications28–30
History of vascular thrombosis APS: increased risk (ORs ranging 3.6–12.7) for pregnancy morbidity31
SLE diagnosis APS: increased risk (OR 6.9) for pregnancy morbidity31 32
aPL profile‡ SLE: strong predictor of adverse maternal and fetal outcomes,19 25 27 33 34 especially for patients with persistent
moderate-to-high aPL titres, LA and multiple aPL positivity (high-risk aPL profile)
APS: high-risk aPL profile correlates with increased risk of maternal vascular thrombotic events during pregnancy (OR 12.1),35
(pre-)eclampsia (OR 2.3),36 37 APS-related pregnancy morbidity (OR 9.2),31 IUGR (OR 4.7),36 preterm birth38 39
Anti-Ro/SSA, anti-La/SSB antibodies Linked to development of neonatal lupus, including a low risk (0.7–2%) for CHB (especially if moderate-to-high anti-Ro
titres);40–43 weak association with other pregnancy complications44
End-stage organ damage and associated
comorbidities
45 46
General risk factors 47
Maternal age
Arterial hypertension Increased risk for pregnancy loss (OR 2.4,33 RR 2.9),48 preterm birth18 24 27 and IUGR (OR 6.8)15
Diabetes mellitus 49
Overweight/obesity
Thyroid disease 50
Nicotine and alcohol use 28
Immunisations§
*Diagnosed by validated SLE activity indices and/or physician judgement.
†Evaluated by renal function tests (serum creatinine, blood urea nitrogen) and urinalysis (proteinuria urine sediment).
‡Includes LA, aCL IgG/IgM, aβ2GPI IgG/IgM. The level of positivity of aCL and aβ2GPI antibodies (low vs medium–high) should be defined according to the single assay’s characteristics.
§If negative serology, evaluate whether immunisations can be performed prior to pregnancy (eg, rubella).
aCL, anticardiolipin antibodies; aβ2GPI, anti-β2-GPI antibodies; anti-dsDNA, anti-double-stranded DNA antibodies; aPL, antiphospholipid antibodies; CHB, congenital heart block; IUGR,
intrauterine growth restriction; LA, lupus anticoagulant; PE, pre-eclampsia; RR, relative risk.
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discussed with the patient by weighing the individual risk
factors, including general (hypertension, obesity, tobacco use,
family history of hormonal-dependent cancers)61 and disease-
related risk factors, particularly disease activity and thrombotic
risk (emphasis on antiphospholipid antibodies (aPLs)).
The intrauterine device (IUD) can be offered to all patients
unless there is a gynaecological contraindication. Copper IUD
can be used in any patient, while levonorgestrel-containing IUD
should be considered only if the beneﬁts of the released
hormone (such as the reduction of excessive menstrual bleeding
due to anticoagulation)62 outweigh the risk of thrombosis.61
The safety of the combined (oestrogen plus progestin) and
progestin-only pill in SLE patients with inactive or stable
active SLE and negative aPL has been demonstrated in rando-
mised controlled trials (RCTs).63 64 In women with positive aPL
(with or without deﬁnite APS), contraception with combined
hormones (oral pill, vaginal ring, transdermal patch) should be
discouraged. In young women with myocardial infarction or
ischaemic stroke and positive lupus anticoagulant, the use of the
combined pill increased the risk of arterial events compared
with non-users.65 In fully anticoagulated patients carrying a
low-risk aPL proﬁle, oestrogens might be considered for persist-
ent gynaecological disorders not otherwise managed. Compounds
containing progestin only (pill, subcutaneous depot injections)
are suitable for these women, although their use should be
weighed against the risk of thrombosis. Progestin-only emer-
gency contraception is not contraindicated in patients with SLE
and/or APS.
Risk factors for reduced fertility
Few studies have assessed fertility in women with SLE and/or
APS by means of hormonal levels (including the anti-Müllerian
hormone) or antral follicle count (examined by ultrasound).
There is no concrete evidence that the disease per se decreases
fertility.66–69
However, active disease, especially lupus nephritis, and the
use of immunosuppressive drugs may negatively impact on fer-
tility. Alkylating agents such as cyclophosphamide (CYC) may
cause menstrual irregularities and premature ovarian failure
(POF), which is age- and dosage dependent.70 71
Similar to the general population, women with SLE and/or
APS should be counselled on fertility issues, especially on the
negative impact of increasing age (general tendency to postpone
childbearing) and certain lifestyle exposures (tobacco use,
alcohol consumption). In non-life-threatening disease, treatment
with alkylating agents should be balanced against the risk of
ovarian dysfunction; rather, less gonadotoxic regimens should
be considered.72 In the presence of multiple risk factors for
impaired fertility, ovarian reserve may be assessed in patients
with SLE at a younger age than recommended for the general
population.73
Fertility preservation
Limited data are available on fertility preservation methods in
menstruating women with SLE who require treatment with
alkylating agents. Cryopreservation of ovarian tissue or oocytes/
embryos are poorly investigated options74 75 and require specia-
lised centres, which may not be easily accessible.
The most extensively studied method for POF prevention in
patients with SLE involves gonadotropin-releasing hormone
analogues (GnRH-a), with a good safety and efﬁcacy proﬁle
(RR 0.12).76 GnRH-a have been efﬁcacious in patients with
cancer.77 78 GnRH-a are likely to protect against POF, but there
are no data on subsequent pregnancies in patients with SLE.
They can cause menopause-like symptoms, which are fully
reversible upon discontinuation. A study in childhood-onset
patients with SLE aged <21 years suggested that GnRH-a
should be administered 22 days before CYC is started or contin-
ued.79 It is nevertheless recommended to start the GnRH-a
prior to or concomitantly to initiation of the alkylating agent.
Assisted reproduction techniques
Evidence on the efﬁcacy and safety of ARTs (ovulation induction
therapy and in vitro fertilisation) in women with SLE and/or
APS comes from observational studies.80–83 Efﬁcacy in terms of
pregnancy rate is comparable with that in the general population
(up to 30%). ARTs are generally safe if the patient has quiescent
disease and is on appropriate antithrombotic treatment if aPL
positive. Although it is challenging to deﬁne a single protocol,
some general measures for prophylaxis in aPL-positive women
undergoing ovarian stimulation can be suggested. The type
(low-dose aspirin (LDA); low molecular weight heparin
(LMWH)) and dosage (prophylactic vs full anticoagulant) of
antithrombotic treatment should be recommended as during
pregnancy according to the individual risk proﬁle. LDA should
be stopped three days before egg retrieval and resumed the fol-
lowing day. Patients taking LMWH should stop it at least
12 hours prior to the procedure and resume it the very same
day as long as there is no bleeding. Patients with positive aPL
who are not taking LDA during the ovarian stimulation period
should start LDA on the day of the embryo transfer, usually in
combination with LMWH (which will be continued during
pregnancy).
Ovarian hyperstimulation syndrome can be avoided by milder
hormonal stimulation or GnRH antagonist protocol.84 The use
of the ‘natural cycle’ method is another option, although
associated with a lower rate of induced pregnancy. The ART
induction protocol should be tailored to the individual patient,
balancing the safety and effectiveness of the procedure.
Predictive biomarkers for maternal disease activity
in SLE pregnancy
Active SLE during pregnancy, assessed by validated disease
activity indices22 56 and/or physician global assessment,20 is
associated with increased risk for maternal and/or fetal compli-
cations (see also paragraph on Preconception counselling and
risk stratiﬁcation). Pregnancy-speciﬁc SLE activity indices have
been developed and validated for their sensitivity in detecting
changes in disease activity and diagnosing ﬂares (see online sup-
plementary table S4).85 86 Physicians should be aware of preg-
nancy physiological changes that can resemble SLE symptoms
and signs.87 Renal activity correlates with adverse pregnancy
outcomes and should be monitored by means of urine protein
excretion, urine sediment analysis (glomerular haematuria,
urinary casts) and serum creatinine level/glomerular ﬁltration
rate.33 49 52 Serological markers are useful in monitoring SLE
activity and in the differentiation between disease exacerbation
(declining serum C3/C4 levels (even within the normal range)
and/or increasing anti-double stranded DNA titres) and pre-
eclampsia.88 89 Smaller increases in serum C3 levels from preg-
nancy onset to the second or third trimester19 as well as sero-
logical activity (as deﬁned above) that develops during
pregnancy, especially in the context of clinical SLE activity, have
been associated with increased risk for pregnancy loss,19 90
intrauterine growth restriction (IUGR)91 and preterm
birth.19 48 89 90 92
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Pregnancy monitoring
Pregnant women with SLE and/or APS should follow the local
protocols applied to pregnancies at high risk for hypertensive
disorders and/or placental insufﬁciency, adjusting the frequency
and modality of fetal surveillance according to the maternal
and/or fetal status (box 1). Fetal surveillance based on biometric
and Doppler ﬁndings during the third trimester, and particularly
the distinction between early and late IUGR, helps to better
tailor the time of delivery and reduce perinatal morbidity and
mortality.93–97 Umbilical and uterine arteries Doppler sonog-
raphy at 20–24 weeks has good negative predictive value but
modest positive predictive value (especially in the absence of
biometric signs of fetal growth restriction later in pregnancy)
for placental-associated pregnancy disorders such as pre-
eclampsia and IUGR. The mode (vaginal vs caesarean section)
and timing of delivery are inﬂuenced by maternal (hypertensive
disorders, anticoagulation status) as well as fetal conditions
during pregnancy.
Fetal echocardiography is indicated if there is suspected fetal
dysrhythmia or myocarditis, especially in the context of positive
maternal anti-Ro/SSA or anti-La/SSB antibodies. Other tests
(electrocardiogram plus Holter monitor, magnetocardiography,
gated-pulsed Doppler technique, velocity-based fetal kinetocar-
diogram) might detect subtle signs of the development of con-
genital heart block (CHB), but are not currently recommended
as standard practice.98 CHB associated with anti-Ro/SSA and/or
anti-La/SSB has 16% recurrence rate in women with a previ-
ously affected child; therefore, it is recommended to perform
serial fetal echocardiograms weekly from 16 weeks of gestation
onwards.98 Considering the low risk (0.7–2%) for CHB in
women with no previous CHB, it is unclear whether intensive
monitoring (weekly/biweekly between 16 and 26 weeks of gesta-
tion and less frequently afterwards)98 in the general population
of anti-Ro/La-positive women is cost-effective. Moreover, there
is no proven efﬁcacy of protocols for the prevention or treat-
ment of complete CHB.99 100 The efﬁcacy of maternal ﬂuori-
nated steroids has not been established in large cohorts101–104
despite initial reports of favourable effects in cases of incom-
plete CHB, cardiomyopathy, endocardial ﬁbroelastosis and
hydrops fetalis.99 Given the potential of ﬂuorinated steroids for
major maternal and fetal side effects, the beneﬁt for fetuses with
CHB should be stratiﬁed according to the presence of risk
factors for adverse outcome.99 Despite its unproven beneﬁt, the
current practice of intensive surveillance for CHB onset in
women with positive anti-Ro/SSA and/or anti-La/SSB antibodies
and no previous child affected by CHB carries no risk and is
well accepted by the mothers.105
Drugs for prevention and management of SLE ﬂares during
pregnancy
A single randomised, placebo-controlled study60 as well as non-
randomised evidence24 33 56 supports the beneﬁcial role of
HCQ in controlling disease activity and preventing ﬂare-ups
during pregnancy. Uncontrolled studies suggest an acceptable
beneﬁt/risk ratio of oral glucocorticoids,22 106 azathioprine59 107
and calcineurin inhibitors (ciclosporin A, tacrolimus)108 109 in
controlling SLE activity during pregnancy. In moderate-to-severe
ﬂares, additional modalities can be considered, such as high-dose
glucocorticoids (including pulse intravenous therapy),110 111 intra-
venous immunoglobulin20 22 and plasmapheresis (may be also
used in refractory nephrotic syndrome).112 113 CYC should not
be administered during the ﬁrst trimester of pregnancy due to
risk for fetal loss (OR 25.5)20 114 and should be reserved only for
the management of severe, life-threatening or refractory SLE
manifestations during the second or third trimester. Available data
are not sufﬁcient to evaluate the risk of using belimumab in preg-
nancy115 and the drug should not be used unless the beneﬁt out-
weighs the risk to the fetus. Mycophenolic acid, methotrexate
and leﬂunomide should be avoided due to known or possible
teratogenicity.116 To this end, collaborative groups have developed
recommendations for the use of antirheumatic drugs before and
during pregnancy and lactation.111 117 118
Adjunct treatment during pregnancy
Use of HCQ is recommended in women with SLE preconcep-
tionally and throughout pregnancy.33 56 60 A beneﬁcial role has
also been suggested for APS pregnancies,119–121 but at present
there is insufﬁcient data to recommend its routine use in these
patients. HCQ may reduce the odds of CHB occurrence in
fetuses exposed to maternal anti-Ro/SSA antibodies, especially
in mothers who already had a child with CHB.40 122
The protective role of LDA against preterm and severe pre-
eclampsia has been established in non-autoimmune patients.123 124
Accordingly, women with SLE at higher risk of pre-eclampsia
including those with lupus nephritis or positive aPL will beneﬁt
from LDA, preferably given preconceptionally or no later than
gestational week 16.123 124
In women with deﬁnite obstetric APS, combination treatment
with LDA and heparin is recommended to decrease the risk of
adverse pregnancy outcomes.16 125–127 Statistically signiﬁcant
results have been demonstrated only for unfractionated heparin
in RCTs. However, LMWH is preferable for practical reasons
and has shown comparable efﬁcacy in prospective studies.128 129
Moreover, patients with positive aPL but with no deﬁnite classi-
ﬁcation of APS will beneﬁt from combination therapy if they are
considered at moderate to high risk of maternal and fetal com-
plications (see online supplementary table S5).
In addition, other regimens such as prednisolone 10 mg/day
in the ﬁrst trimester, intravenous immunoglobulin or plasma-
pheresis can be considered for selected patients with APS
(refractory obstetric APS, women with previous thrombosis, par-
ticularly previous or new cerebrovascular events, women with
triple aPL positivity).119 130–133
Box 1 Ultrasonographic fetal surveillance recommended
for pregnant women with systemic lupus erythematosus
and/or antiphospholipid syndrome43 45–48
▸ Routine ultrasonographic screening
– First trimester (11–14 weeks of gestation).
– Second trimester (with Doppler, preferably at
20–24 weeks of gestation).
▸ Supplementary fetal surveillance in the third trimester at
monthly intervals
– Doppler sonography of the umbilical artery, uterine
arteries, ductus venosus and middle cerebral artery
(particularly in fetuses that have been identiﬁed to suffer
from early intrauterine growth restriction (IUGR), ie, prior
to 34 weeks of gestation).
– In cases of late IUGR (diagnosed after 34 weeks), reduced
abdominal circumference growth velocity and/or a
reduced cerebroplacental ratio at Doppler investigation
was shown to identify fetuses at higher risk of poor
perinatal outcome (Doppler of the umbilical artery alone
is insufﬁcient).
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As recommended in the general population, supplementation
with calcium, vitamin D and folic acid should be offered to
patients with SLE and/or APS, with particular consideration to
those with low circulating levels of 25-OH vitamin D in the ﬁrst
trimester of gestation and receiving glucocorticoids and/or
heparin for their detrimental effects on bone mass.
Menopause and hormone replacement therapy
The efﬁcacy and safety of hormone replacement therapy (HRT)
(oestrogen plus progestin) in selected patients with SLE has
been illustrated in RCTs.134–136 Beneﬁt was demonstrated
mainly in vasomotor and other hypoestrogenism symptoms. No
signiﬁcantly increased risk of severe lupus exacerbations during
12–24 months of HRTwas found, although there was a modest
increase in mild-to-moderate ﬂares.132 There was no increased
risk of thrombosis and cardiovascular events, although one of
the RCTs included only patients with negative aPL and no previ-
ous cardiovascular events132 and another did not detail the aPL
proﬁle.63 Two cohort studies with long-term follow-up did not
report signiﬁcantly increased risk of cardiovascular events
during HRT,137 138 although limitations in power and design
preclude ﬁrm conclusions. Consequently, HRT should be
reserved for the management of severe and disabling vasomotor
menopausal symptoms, preferably in SLE women with stable/
inactive disease and negative aPL. In patients with positive aPL,
the use of HRT should be carefully weighed against thrombotic
and cardiovascular risks. If menopause symptoms necessitate
HRT, it seems reasonable to start it as early as possible to gain
an added beneﬁt for bone protection.139 Optimal duration of
HRT in patients with SLE and/or APS is not known, but it
seems reasonable to recommend it for the shortest possible
duration.140 141
Screening for malignancies
Women with SLE are not at increased risk of breast, ovarian and
endometrial cancer compared with the general population,142 143
and, therefore, should follow the current population screening
protocols for these malignancies. Conversely, women with SLE
are at higher risk of cervical dysplasia (but not cervical
cancer),144–147 vagina and vulva cancers,142 147 likely associated
with human papillomavirus (HPV) infection. Women with SLE
exposed to immunosuppressive drugs, particularly CYC in a
cumulative dose-dependent fashion, are at higher risk of cervical
dysplasia.148–151 The suggested timing for Papanicolaou (PAP)
smear examination would be once a year in heavily immunosup-
pressed patients or according to the local screening programme
in low-risk patients. Subgroups of women with SLE (Caucasian,
younger age, lower education, high SLE damage) may be at risk
for poorer adherence to screening programmes.152 153
HPV vaccination
HPV vaccination is currently offered to female and male adoles-
cents for preventing precancerous growths and cancer in the
cervix and in the genital area. There are reports of venous
thromboembolic events (VTEs) associated with the quadrivalent
HPV vaccine. However, of the 31 cases (0.2/100 000 doses
vaccine) with documented VTE, 90% had a known risk factor
for VTE (APS in two cases).154
Prospective studies have demonstrated efﬁcacy and safety of
HPV vaccination in patients with SLE,155 156 although seroconver-
sion rates may be lower in patients receiving steroids and immuno-
suppressive agents. A few cases of severe SLE ﬂares or abrupt SLE
onset after HPV vaccination have been reported.157–159 In accord-
ance with the EULAR recommendations,160 we recommend that
HPV vaccination be offered to young women with stable/inactive
SLE and/or APS, according to local protocols, with particular
caution in those with high-risk aPL proﬁle.
The points to consider and the research agenda suggested by
the Task Force Members are reported in box 2.
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Box 2 Points to consider and research agenda
▸ Reproductive issues are of paramount importance for women
with systemic lupus erythematosus (SLE) and/or
antiphospholipid syndrome (APS) and should be addressed
on a regular basis by healthcare providers.
▸ Preconception counselling and risk stratiﬁcation are essential
for prevention of unwanted complications during pregnancy.
▸ The use of hormonal contraception or replacement therapy is
feasible but must be weighed against the individual risk of
thrombosis.
▸ The preservation of fertility should be mentioned while
counselling about lifestyles and considered in the treatment
choice. Validated protocols for assisted reproduction
techniques in patients with SLE and/or APS are needed.
▸ Predictive biomarkers for maternal disease activity during
SLE pregnancy should be expanded with particular focus on
the prediction of pre-eclampsia.
▸ Pregnancy monitoring in SLE and/or APS women should aim
at the identiﬁcation of placental insufﬁciency with fetal
growth restriction in order to decide the best timing for
delivery and reduce the risk of perinatal morbidity and
mortality.
▸ The cost-effectiveness of intensive surveillance with fetal
echocardiography in patients with positive anti-Ro/SSA and
anti-La/SSB antibodies and no previous child with congenital
heart block remains to be established.
▸ Hydroxychloroquine is beneﬁcial during pregnancy to reduce
the risk of SLE ﬂares and of poor obstetrical outcomes. More
data are needed to support its beneﬁt in APS pregnancies.
▸ The beneﬁts of cancer surveillance and prevention of
gynaecological malignancies need to be communicated to
patients.
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